Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $66.6667.

A number of brokerages recently commented on RVPH. Maxim Group downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.43 on Wednesday. The stock’s 50-day moving average is $0.56 and its 200 day moving average is $2.49. The company has a market cap of $5.63 million, a PE ratio of -0.11 and a beta of 0.47. Reviva Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $17.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Analysts expect that Reviva Pharmaceuticals will post -2.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in Reviva Pharmaceuticals in the second quarter worth about $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 3rd quarter valued at approximately $37,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. State Street Corp grew its holdings in shares of Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after acquiring an additional 256,500 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares in the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.